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Abstract 
The incidence of cefotaximase (CTX-M)-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli 
has increased dramatically in humans and animals since the middle of the last century. Escherichia coli that produce 
CTX-M β-lactamase represent a major cause of urinary tract infections, and pose a significant therapeutic challenge to 
both human and veterinary medicine. As data on uropathogenic CTX-M-producing strains in cats are limited, the aim of 
this study was to describe the genetic character and antibiotic resistance phenotypes of CTX-M-producing E. coli 
isolated from cats with cystitis. Seven of 15 E. coli bacteria isolated from 138 urine samples had the CTX-M gene and 
were therefore included in this study. These isolates were screened by polymerase chain reaction for the presence of 14 
extra-intestinal virulence factors, class 1 and class 2 integrons, and to identify their phylogenetic groups. Multi-locus 
sequence typing (MLST) of the strains and susceptibility testing (disc diffusion method) were also performed. 
Virulence factor iutA was the most frequent determinant identified (86.7%), and the majority of CTX-M-producing 
strains (n = 5) carried class 1 integrons. MLST allowed us to discriminate four known sequence types (ST131, ST555, 
ST602, ST155) and three novel sequence types (ST3847, ST3848, ST4181). To the best of our knowledge, this is the 
first study to report uropathogenic CTX-M-producing E. coli ST131 in cats in Italy. Accurate diagnostics and prudent 
use of antimicrobials are recommended to avoid the spread of multidrug-resistant pathogens in veterinary medicine 
and to prevent their transmission to humans. 
 
Introduction 
Escherichia coli is an Enterobacteriaceae commonly found in the gastrointestinal tract of mammals; however, 
certain strains can cause a wide spectrum of intestinal and extra-intestinal diseases in humans and animals, 
including cats.
1, 4
 In particular, E. coli has been identified as the most frequent pathogen in cat urinary tract infections 
(UTIs).
5
 The strains that cause UTIs, known as uropathogenic E. coli (UPEC), are characterised by specialised 
virulence factors, which are usually encoded on pathogenicity-associated islands (PAIs), genomic regions that may 
participate in the horizontal transfer of virulence genes.
6
 Recently, the role of pathogenic E. coli in severe extra-
intestinal infections, included UTIs, has been the subject of much research attention because of its importance 
from a veterinary clinical perspective and its zoonotic potential.
6, 7
 Of particular concern is the increasing presence of 
extended-spectrum β-lactamase (ESBL)-producing E. coli; of these, the cefotaximase (CTX-M) family is the most 
prevalent type worldwide.
8
 CTX-M-encoding genes are located commonly on transferable elements (integrons, 
transposons, insertion sequences) carried by plasmids that facilitate the fast spread of resistance.
9 
Besides the spread 
through mobile genetic elements, CTX-M dissemination can also be due to epidemic clones associated with specific 
enzymes, such as CTX-M-15, which is responsible for nosocomial infections and contributes to the current pandemic 
CTX-M scenario.
10
 In particular, a clone of CTX-M-15-producing E. coli, named ST131, was identified recently. 
This clone belongs to a highly virulent phylogenetic group and harbours multidrug-resistant (MDR) plasmids, 
resulting in ST131 becoming a pathogen of significant clinical  concern;  indeed,  a  high  incidence  of both 
community-onset and hospital-acquired infections has been reported.
11
 The aim of this study was to investigate the 
occurrence of CTX-M-producing E. coli obtained from cat urine, and to characterise its genotypic and phenotypic 
features in order to assess the epidemiological characteristics of these strains in the study area. 
 
 
Materials and methods 
Sample collection and CTX-M-producing E. coli identification 
Between February and December 2012, urine samples were collected, by cystocentesis, from 138 cats with 
uncomplicated cystitis.  Feline  patients and/or urine samples were referred to the Teaching Hospital of the 
Department of Veterinary Sciences of the University of Turin. Urine samples were cultured on MacConkey 
agar (Oxoid) and incubated overnight at 37°C. Lactose-fermenting, indole-positive colonies were evaluated 
using the BBL Crystal test (Becton Dickinson), which allowed the identification of 15 E. coli bacteria. All 
urinary isolates were assumed to be uropathogenic, as they were associated with UTI.
12
 The bacterial genomic 
DNA of each isolate was extracted using a commercially available kit (InstaGene DNA; BioRad), according to 
the manufacturer's instructions, and tested for the CTX-M gene by polymerase chain reaction (PCR) using the 
primers and conditions described in Table I.
13  
Of the 15 E. coli isolates identified, seven were CTX-M-positive; 
these strains were stored in Luria-Bertani broth (Oxoid) containing 15% glycerol at -80°C until further use. 
The eight isolates confirmed not to be producers of CTX-M β-lactamases were excluded from the study. 
Detection of resistance genes and integrons All CTX-M-positive amplicons were sequenced and analysed 
using a BLAST search (http://blast.ncbi.nlm.nih. gov) in order to identify the type of CTX-M. The CTX-M-type 
ESBL-producing strains were then tested by PCR to investigate the presence of other β-lactamase genes: 
CMY-2, TEM and SHV (primer sequences and amplification conditions are reported in Table I).
13, 14
 Amplicons 
positive for TEM and SHV were sequenced and analysed to identify the variants. Class 1 and class 2 integrons 
were detected by PCR using primers targeting the Intl and Int2 genes, respectively. Variable regions were 
amplified and sequenced to identify gene cassettes.
15  
 
Multi-locus sequence typing 
Multi-locus sequence typing (MLST) was carried out; the detailed protocol, including allelic type and 
sequence type (ST) assignment methods, is available from the MLST Databases at the Environmental 
Research Institute, University College Cork (http://mlst.ucc.ie/ mlst/dbs/Ecoli). 
Detection of extra-intestinal virulence genes and phylogenetic group 
Each E. coli isolate was screened by PCR for the presence of a range of virulence factors (VFs) associated with 
extraintestinal pathogenic E. coli (ExPEC) (Table I).
16, 22 
The distribution of isolates across phylogenetic groups (A, 
Bl, B2 and D) was determined by triplex PCR.
23
 
Antimicrobial susceptibility testing  
Suseptibility testing was carried out by the disc diffusion method according to the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) criteria guidelines (http://www.EUCAST.org). The 
following antibiotics (Neo-sensitabs; Rosco) were used: amikacin, 30 pg; amoxicillin clavulanate, 30 pg; 
ceftriaxone, 30 pg; cefepime, 30 pg; chloramphenicol, 30 pg; enrofloxacin, 10 pg; gentamicin, 10 pg; imipenem, 
10 pg; nalidixan, 30 pg; nitrofurantoin, 100 pg; piperacillin, 100 pg; spectinomy-cin, 200 pg; streptomycin, 10 
pg; sulphonamide, 240 pg; tetracycline, 30 pg; and trimethoprim, 5 }ig. Results of the antimicrobial 
susceptibility testing were interpreted according to the EUCAST guidelines on veterinary or human 
pathogens (the latter guidelines were used for tetracycline, nalidixan and cefepime). Strains resistant to at 
least three classes of antibiotics (including extended-spectrum cephalosporins, aminoglycosides, carbapen-
ems, quinolones, sulphonamides and trimethoprim) were defined as MDR. 
 
Results 
The genetic character of the CTX-M-producing isolates detected in this study are reported in Table 2. The 
following variants were identified: CTX-M-14 (n = 5), CTX-M-1 (n = 1), and CTX-M-15 (n = 1). Two strains also 
contained TEM-1 and CMY-2 β-lactamases. 
Four isolates were identified as known STs present in the MLST database: ST131, ST555 (clonal complex 538), 
ST602 (clonal complex 446) and ST155 (clonal complex 155). Three were novel STs (ST3847, ST3848 and 
ST4181) not yet assigned to a clonal complex. VF screening revealed the presence of fimA, hh/A, cnfl, iutA 
and fyuA, typical virulence determinants of UPECs. The iut gene was common in 6/7 strains, and was 
always associated with other VFs. Moreover, the presence of some virulence genes, such as hh/A, cnfl, 
fimA,fyuA and malX, suggests the presence of PAIs
24
,
26
 in all E. coli strains tested, except in one isolate (cat 3). 
Five CTX-M-type E. coli strains contained class 1 inte-grons; however, the gene cassettes aadA and dfrAl+aadA 
(conferring resistance to trimethoprim and streptomy-cin-spectinomycin, respectively) were found in only 
two isolates. All the class 1 integron-positive isolates were nalidixic acid-resistant, and one isolate contained 
class 2 integrons. 
With regard to antibiotic susceptibility (Table 3), all strains exhibited an MDR phenotype. The CTX-M-
producing isolates were resistant to several β-lactam antibiotics. Moreover, all were susceptible to imipenem 
and three to amoxicillin clavulanate. 
 
Discussion 
This study shows that almost half of the E. coli bacteria isolated from cats with UTI were MDR, CTX-M-
producing strains. As expected, all CTX-M-positive strains possessed several VFs linked to the pathogenicity 
of ExPEC, including papC, sfa, fyuA and hh/A, putative contributors of urovirulence. 
Besides CTX-M genes, we identified TEM-1 and CMY-2 genes in two strains. This finding confirms that ESBL-
producing E. coli strains may carry more than one β-lactamase gene.27 The majority of CTX-M-producing 
strains had class 1 integrons, suggesting the frequent presence of these integrons in ESBL-producing 
strains, and that they may influence the level of antibiotic resistance. The aacA7 cassette gene (responsible for 
resistance to amikacin) was absent in all samples, including the amikacin-resistant isolate, suggesting the 
existence of other resistance mechanisms of inactivation of aminoglycosides.
28
 CTX-M-14 was the most 
common ESBL resistance gene found. Only one strain (cat 6) contained the CTX-M-15 gene, and this strain 
belonged to ST131, presenting the typical characteristics of this sequence type, such as the presence of fyuA, 
iutA, kpsMII and malX, and allocation to the B2 phylogroup.
29
 
Over the last decade, the ST131 virulent pandemic clone has emerged in hospitals and in the community 
worldwide, causing outbreaks of MDR infections across the globe.
30
 It has been frequently described as a 
urinary pathogen in humans,
31
 and a fatal case of urosepsis associated with a multi-resistant strain of E. coli 
ST131 was reported recently
30
 Although rarely isolated from companion animals, a recent report found E. coli 
ST131 to distribute among human and animal household members in Australia, suggesting serious clinical 
and public health implications.
32
 In Europe, until now, ST131 has only been isolated from dogs, horses,
33
 poultry
34
 
and pigs
35
. Huber et al
3
 identified uropathogenic CTX-M-15 E. coli in dogs and cats; however, they did not find 
any ST131 clones in their study. Therefore, to the best of our knowledge, this is the first report of 
uropathogenic CTX-M-producing E. coli ST131 in cats in Italy. 
We also detected the presence of ST155, recently isolated in E. coli carrying CTX-M-1 from Austrian cats
36
 and 
Swedish broilers,
37
 and ST602, recently identified in CTX-M-14 isolates from avian species in Italy
38
 and from 
Swedish broilers.
37
 Interestingly, the fourth ST identified (ST555) has been reported in E. coli isolated from 
patients with asymptomatic bacteriuria.
39
In our study, a high rate of quinolone resistance was observed. 
This finding can be ascribed to the fact that plasmids carrying the CTX-M genes  often harbour resistance 
genes for other antibiotic classes, such as fluoroquinolones and aminoglycosides.
40 
Indeed, as expected, the ST131 
strain in our study was fluoroquinolone-resistant. Three strains were susceptible to amoxicillin clavulanate. 
However, despite the fact that ESBL-producing strains may appear susceptible to a penicillin/β-lactamase inhibitor 
combination and cephalosporins in vitro, the clinical use of these drugs remains controversial and should be 
approached with caution. From a clinical point of view, our results recommend the prudent use of antimicrobials in cats 
affected by UTIs as the emergence of resistant uropathogens is likely to negatively affect the effectiveness of empiric 
therapy. The antimicrobial agents most commonly used to treat feline uncomplicated UTIs include β-lactams, fluoroqui-
nolones and the drug combination trimethoprim plus sulfamethoxazole. However, according to our results, these drugs 
should not be used as first-line drug therapy unless susceptibility testing is performed. Moreover, owing to the risk of 
blindness, the clinical use of fluoroquinolones for feline UTIs should be limited.
41
 The administration of last-line 
antimicrobials from human medicine for veterinary purposes should also be discouraged or avoided despite the 
demonstrated efficacy of imipenem in the treatment of antimicrobial resistant infections in cats.
42, 43
 In contrast, although 
the use of nitrofurantoin in cats presents some disadvantages, such as high toxicity and poor pharmacokinetic 
characteristics, this drug should be considered as a therapeutic option for urinary infections caused by ESBL-producing 
E. coli.
44
 However, as nitrofurantoin is not licensed for animal use in Italy, the rationale for its off-label administration 
could be justified on the basis of its benefit/risk ratio. This should be complemented with a pharma-covigilance report 
concerning the lack of efficacy of first-line authorised antimicrobials. Feline lower urinary tract diseases are seldom caused 
by bacteria, but more often by obstructive idiopathic cystitis, urethral plugs or urinary calculi.
5, 45
 Nevertheless, in many 
instances these conditions are treated with antimicrobials, thus promoting the selection of resistant strains. It is therefore 
recommended that the necessary diagnostics are performed before starting antimicrobial therapy for feline UTIs. At the 
very least, initial antimicrobial selection should be based on urine sediment examination to identify the presence of 
bacteria and on urine pH.
41
 
 
Conclusions 
This study is the first to report the presence of the uropathogenic E. coli ST131 isolate producing CTX-M-15 in cats in 
Italy. Considering that pets and owners share extra-intestinal E. coli, basic hygiene measures and infection control 
strategies should be implemented, especially in veterinary clinics and teaching hospitals, in order to prevent the 
diffusion of this microorganism. Finally, the prudent use of antimicrobials and accurate diagnostic procedures should be 
emphasised to avoid the further spread of MDR pathogens in veterinary medicine. 
 
 
 Table 1. PCR primers used in the study to detect β-lactamase and extra-intestinal virulence factor genes. 
 
 
Target 
gene 
Primer sequence (5’ to 3’) 
Product size  
(bp) 
Annealing 
temp (°C) 
Reference 
CTX-M 
ATGTGCAGYACCCAGTAARGTKATGGC          
TGGGTRAARTARGTSACCAGAAYCAGCGG 
593        60                      
(13) 
CMY-2 
GCACTTAGCCACCTATACGGCAG 
GCTTTTCAAGAATGCGCCAGG 
758 58 
TEM 
ATAAAATTCTTGAAGAC 
TTACCAATGCTTAATCA 
1075 45 
(14) 
SHV 
TGGTTATGCGTTATATTCGCC 
GCTTAGCGTTGCCAGTGCT 
867 50 
afa 
GCTGGGCAGCAAACTGATAACTCTC 
CATCAAGCTGTTTTGTTCGTCCGCCG 
750 65 
 (16) papC 
GACGGCTGTACTGCAGGGTGTGGCG 
ATATCCTTTCTGCAGGGATGCAATA 
328 61 
sfa 
CTCCGGAGAACTGGGTGCATCTTAC 
CGGAGGAGTAATTACAAACCTGGCA 
410 64 
fimA 
CGGCTCTGTCCCTSAGT 
GTCGCATCCGCATTAGC 
500 52 
 (17) 
iutA 
ATGAGCATATCTCCGGACG 
CAGGTCGAAGAACATCTGG 
587 58 
cdt 
GAAAGTAAATGGAATATAAATGTCCG 
AAATCACCAAGAATCATCCAGTTA 
 
GAAAATAAATGGAACACACATGTCCG 
AAATCTCCTGCAATCATCCAGTTA 
466 
 
466 
55 
 
55 
 (18) 
cnf1 
GGCGACAAATGCAGTATTGCTTGG 
GACGTTGGTTGCGGTAATTTTGGG 
522 60  (19) 
hlyA 
AACAAGGATAAGCACTGTTCTGGCT 
ACCATATAAGCGGTCATTCCCGTCA 
1177 62 
 
 (20) 
fyuA 
TGATTAACCCCGCGACGGGAA 
CGCAGTAGGCACGATGTTGTA 
880 63 
 (21) 
malX 
GGACATCCTGTTACAGCGCGCA 
TCGCCACCAATCACAGCCGAAC 
930 63 
traT 
GGTGTCGTGCGATGAGCACAG 
CACGGTTCAGCCATCCCTGAG 
290 63 
kpsMII 
GCGCATTTGCTGATACTGTTG 
CATCCAGACGATAAGCATGAGCA 
272 63 
clbB 
GATTTGGATACTGGCGATAACCG 
CCATTTCCCGTTTGAGCACAC 
579 55 
 (22) 
  
hra 
CGAATCGTTGTCACGTTCAG 
TATTTATCGCCCCACTCGTC 
162 55 
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